Evidence map›Paper›PMID 33842395›Full record

ArticleFrontiers in cellular and infection microbiology2021

Optimizing Village-Level Targeting of Active Case Detection to Support Visceral Leishmaniasis Elimination in India.

Joy Bindroo, Khushbu Priyamvada, Lloyd A C Chapman, Tanmay Mahapatra, Bikas Sinha, Indranath Banerjee, Prabhas Kumar Mishra, Basab Rooj, Kumar Kundan, Nupur Roy and 6 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Joy BindrooBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Khushbu PriyamvadaBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Lloyd A C ChapmanDepartment of Medicine, University of California San Francisco, San Francisco, CA, United States.
Tanmay MahapatraBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Bikas SinhaBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Indranath BanerjeeBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Prabhas Kumar MishraBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Basab RoojBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Kumar KundanBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.
Nupur RoyNational Vector-Borne Disease Control Programme, Ministry of Health & Family Welfare, Government of India, New Delhi, India.
Naresh Kumar GillNational Vector-Borne Disease Control Programme, Ministry of Health & Family Welfare, Government of India, New Delhi, India.
Allen HightowerIndependent consultant, Bangkok, Thailand.
Madan Prasad SharmaDepartment of Health, Government of Bihar, Patna, India.
Neeraj DhingraNational Vector-Borne Disease Control Programme, Ministry of Health & Family Welfare, Government of India, New Delhi, India.
Caryn BernDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco CA, United States.
Sridhar SrikantiahBihar Technical Support Program, CARE-India Solutions for Sustainable Development, Patna, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: India has made major progress in improving control of visceral leishmaniasis (VL) in recent years, in part through shortening the time infectious patients remain untreated. Active case detection decreases the time from VL onset to diagnosis and treatment, but requires substantial human resources. Targeting approaches are therefore essential to feasibility. Methods: We analyzed data from the Kala-azar Management Information System (KAMIS), using village-level VL cases over specific time intervals to predict risk in subsequent years. We also graphed the time between cases in villages and examined how these patterns track with village-level risk of additional cases across the range of cumulative village case-loads. Finally, we assessed the trade-off between ACD effort and yield. Results: In 2013, only 9.3% of all villages reported VL cases; this proportion shrank to 3.9% in 2019. Newly affected villages as a percentage of all affected villages decreased from 54.3% in 2014 to 23.5% in 2019, as more surveillance data accumulated and overall VL incidence declined. The risk of additional cases in a village increased with increasing cumulative incidence, reaching approximately 90% in villages with 12 cases and 100% in villages with 45 cases, but the vast majority of villages had small cumulative case numbers. The time-to-next-case decreased with increasing case-load. Using a 3-year window (2016-2018), a threshold of seven VL cases at the village level selects 329 villages and yields 23% of cases reported in 2019, while a threshold of three cases selects 1,241 villages and yields 46% of cases reported in 2019. Using a 6-year window increases both effort and yield. Conclusion: Decisions on targeting must consider the trade-off between number of villages targeted and yield and will depend upon the operational efficiencies of existing programs and the feasibility of specific ACD approaches. The maintenance of a sensitive, comprehensive VL surveillance system will be crucial to preventing future VL resurgence.

Indexed as

Leishmaniasis, VisceralHumansIncidenceIndiadisease controlepidemiologyIndiasurveillancevisceral leishmaniasis

Identifiers

PMID33842395
PMCPMC8024562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.